Trial Profile
A Phase 2, Open-Label Study to Assess the Immunogenicity of the 9-Valent Human Papillomavirus Recombinant Vaccine in Patients With Idiopathic CD4 T Cell Lymphocytopenia
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs V 503 (Primary)
- Indications Human papillomavirus infections
- Focus Pharmacodynamics
- 07 Dec 2023 Planned End Date changed from 28 Feb 2024 to 31 Dec 2025.
- 07 Dec 2023 Planned primary completion date changed from 28 Feb 2024 to 31 Dec 2025.
- 07 Jan 2023 Planned End Date changed from 28 Feb 2023 to 28 Feb 2024.